TRVI Stock Forecast & Price Target

Trevi Therapeutics Inc. is advancing its investigational therapy Haduvio, which has demonstrated a significant ~56% placebo-adjusted cough reduction in its Phase 2a RIVER trial, surpassing competing treatments like camlipixant. The company's financial position shows improvement, with a narrowed fourth-quarter net loss of $8.3 million driven by reduced clinical development expenses and increased interest income, indicating effective cost management. With a robust balance sheet and a clear regulatory pathway for approval through the 505(b)(2) process, Trevi is well-positioned to execute multiple concurrent trials in chronic cough and expand its market presence without immediate financing risks.

Trevi Therapeutics Inc faces significant financing risk as the company continues to accumulate considerable and rising operating expenses associated with the clinical development of its investigational therapy Haduvio. In the fourth quarter of 2025, the company reported a loss of $8.3 million, leading to an overall net loss of $42.8 million for the fiscal year, despite efforts to reduce research and development spending. Additionally, while Trevi ended 2025 with $188.3 million in cash, the ongoing high operational costs and the need for further funding raise concerns about the sustainability of its financial position moving forward.